Citations

Mayo Clinic

Showing 10 of 108523 citations.

Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
Strozzi, Isabella, Nolan, Sarah J, Sperling, Michael R. , Wingerchuk, Dean M. , Sirven, Joseph I , Nolan, Sarah J, Sperling, Michael R

Cochrane Database of Systematic Reviews | February 12, 2015 | Volume: 2015 | Issue: 4 | Pages: No page available

10.1002/14651858.cd001902.pub2 | PMID 25922863 Get It

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Boysen, Justin C. , Nelson, Michael, Secreto, Charla, Warner, Steven L. , Bearss, David J. , Lesnick, Connie , Ghosh, Asish K. , Bearss, David J. , Boysen, Justin, Sinha, Sutapa , Shanafelt, Tait D. , Kay, Neil E.

Clinical Cancer Research | February 11, 2015 | Volume: 21 | Issue: 9 | Pages: 2115-2126

10.1158/1078-0432.ccr-14-1892 | PMID 25673699 Get It

Abstract Purpose: B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches. We previously found that Axl receptor tyrosine kinase (RTK) plays a critical role in CLL B-cell survival. Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clinical trial to treat patients with CLL. Experimental Design: Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated. Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs). Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells. Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to determine any synergistic/additive effects of the combination. Results: CLL B cells overexpress Tyro3, but not MER. Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells. TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges. Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903–induced apoptosis. A marked reduction of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition. Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis. Conclusions: Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL. Clin Cancer Res; 21(9); 2115–26. ©2015 AACR.
Spontaneous coronary artery thrombosis in the setting of active lupus mesenteric vasculitis
Reddy, Yogesh N.V. , Sundaram, Varun , Tam, Marty , Parikh, Sahil A. , Nishimura, Rick

Lupus | February 11, 2015 | Volume: 24 | Issue: 8 | Pages: 885-888

10.1177/0961203315570167 | PMID 25672373 Get It

A 33-year-old male with systemic lupus erythematosus (SLE) presented with acute abdominal pain and was found to have lupus mesenteric vasculitis on imaging and during exploratory laparotomy. Post laparotomy he continued to have persistent nausea and dyspepsia and an electrocardiogram showed evidence of an inferior ST elevation myocardial infarction (STEMI). Emergency cardiac catheterization showed evidence of thrombotic right coronary artery occlusion. His coronaries were otherwise normal with no evidence of underlying coronary artery disease. Extensive workup with trans-esophageal echo, serologies for antiphospholipid antibody syndrome (APS) and bubble study was negative. This effectively ruled out Libman–Sacks endocarditis, APS-induced arterial thrombus and paradoxical emboli as potential causes of his STEMI. By exclusion of other causes, the etiology of his STEMI was felt to be secondary to in-situ coronary artery thrombosis in the setting of active SLE. To the best of our knowledge, this is the first report of a patient with SLE presenting with both lupus mesenteric vasculitis and in-situ coronary arterial thrombosis in the absence of APS.
Clinical Pharmacology & Therapeutics: The Next Five Years
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Clinical Pharmacology & Therapeutics | February 11, 2015 | Volume: 97 | Issue: 1 | Pages: 2-6

10.1002/cpt.22 | PMID 25670374 Get It

It has been nearly ten years since we joined the editorial organization of Clinical Pharmacology & Therapeutics (CPT), as part of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) family. During that tenure, the primary mandate has been the growth of CPT, recognized as one of the key voices of the discipline and the Society. Set goals were realized in concert with a strong editorial team, a diverse editorial board, a dedicated editorial staff, and outstanding authors, leveraging a leading publishing infrastructure and responding to the needs of a global readership, expanding membership, and the discipline as a whole. The impending decade anniversary, and the transition to a new publisher, offers a natural juncture to reflect on progress, and chart plans for the future of the Journal.
Relationship of Genetic Variation in the Serotonin Transporter Gene ( SLC6A4 ) and Congenital and Acquired Cardiovascular Diseases
Moyer, Ann M. , Walker, Denise L., Avula, Rajeswari, Kung, Simon , Bryant, Sandra C. , Edwards, Kelly K., Black, John L. , Karpyak, Victor M. , Shinozaki, Gen , Jowsey‐Gregoire, Sheila G. , Ehlers, Shawna L. , Romanowicz, Magdalena , Litzow, Mark R. , Rundell, James R., Hooten, W. Michael , Baudhuin, Linnea M. , Lapid, Maria I. , Hogan, William J. , Karpyak, Victor

Genetic Testing and Molecular Biomarkers | February 11, 2015 | Volume: 19 | Issue: 3 | Pages: 115-123

10.1089/gtmb.2014.0250 | PMID 25671637 Get It

A Survey and Review of Telemedicine License Portability
Rogove, Herbert J., Amoateng, Benjamin, Binner, Jennifer, Sanders, Richard B., Demaerschalk, Bart M.

Telemedicine and e-Health | February 11, 2015 | Volume: 21 | Issue: 5 | Pages: 374-381

10.1089/tmj.2014.0116 | PMID 25671795 Get It

Transformation of standardized clinical models based on OWL technologies: from CEM to OpenEHR archetypes
Legaz-García, María del Carmen, Marcos, Menarguez-Tortosa , Fernández‐Breis, Jesualdo Tomás , Tao, Cui , Chute, Christopher G. , Legaz-García, María del Carmen, Tao, Cui

Journal of the American Medical Informatics Association | February 11, 2015 | Volume: 22 | Issue: 3 | Pages: 536-544

10.1093/jamia/ocu027 | PMID 25670753 Get It

Abstract Introduction The semantic interoperability of electronic healthcare records (EHRs) systems is a major challenge in the medical informatics area. International initiatives pursue the use of semantically interoperable clinical models, and ontologies have frequently been used in semantic interoperability efforts. The objective of this paper is to propose a generic, ontology-based, flexible approach for supporting the automatic transformation of clinical models, which is illustrated for the transformation of Clinical Element Models (CEMs) into openEHR archetypes. Methods Our transformation method exploits the fact that the information models of the most relevant EHR specifications are available in the Web Ontology Language (OWL). The transformation approach is based on defining mappings between those ontological structures. We propose a way in which CEM entities can be transformed into openEHR by using transformation templates and OWL as common representation formalism. The transformation architecture exploits the reasoning and inferencing capabilities of OWL technologies. Results We have devised a generic, flexible approach for the transformation of clinical models, implemented for the unidirectional transformation from CEM to openEHR, a series of reusable transformation templates, a proof-of-concept implementation, and a set of openEHR archetypes that validate the methodological approach. Conclusions We have been able to transform CEM into archetypes in an automatic, flexible, reusable transformation approach that could be extended to other clinical model specifications. We exploit the potential of OWL technologies for supporting the transformation process. We believe that our approach could be useful for international efforts in the area of semantic interoperability of EHR systems.
Muscle inflammation susceptibility: a prognostic index of recovery potential after hip arthroplasty?
Bamman, Marcas M. , Evans, Richard P., Stec, Michael J. , Kelly, Neil, Gruenwald, Johannes , Corrick, Katie L., Trump, Jesse R., Singh, Jasvinder A. , Ferrando, Arny A. , Singh, Jasvinder A

American Journal of Physiology-Endocrinology and Metabolism | February 11, 2015 | Volume: 308 | Issue: 8 | Pages: E670-E679

10.1152/ajpendo.00576.2014 | PMID 25670829 Get It

While elective total hip arthroplasty (THA) for end-stage osteoarthritis (OA) improves pain, mobility function, and quality of life in most cases, a large proportion of patients suffer persistent muscle atrophy, pain, and mobility impairment. Extensive skeletal muscle damage is unavoidable in these surgical procedures, and it stands to reason that poor recovery and long-term mobility impairment among some individuals after THA is linked to failed muscle regeneration and regrowth following surgery and that local muscle inflammation susceptibility (MuIS) is a major contributing factor. Here we present results of two integrated studies. In study 1, we compared muscle inflammation and protein metabolism signaling in elective THA ( n = 15) vs. hip fracture/trauma (HFX; n = 11) vs. nonsurgical controls (CON; n = 19). In study 2, we compared two subgroups of THA patients dichotomized into MuIS (+) ( n = 7) or MuIS (−) ( n = 7) based on muscle expression of TNF-like weak inducer of apoptosis (TWEAK) receptor (Fn14). As expected, HFX demonstrated overt systemic and local muscle inflammation and hypermetabolism. By contrast, no systemic inflammation was detected in elective THA patients; however, local muscle inflammation in the perioperative limb was profound in MuIS (+) and was accompanied by suppressed muscle protein synthesis compared with MuIS (−) . Muscle from the contralateral limb of MuIS (+) was unaffected, providing evidence of a true inflammation susceptibility localized to the muscle surrounding the hip with end-stage OA. We suggest MuIS status assessed at the time of surgery may be a useful prognostic index for muscle recovery potential and could therefore provide the basis for a personalized approach to postsurgery rehabilitation.
Endoscopic radiofrequency ablation for early esophageal squamous cell neoplasia: report of safety and effectiveness from a large prospective trial
He, Shun , Bergman, Jacques , Zhang, Yueming , Weusten, Bas L. , Xue, Liyan , Qin, Xiumin, Dou, Lizhou, Liu, Yong , Fleischer, David E., Lü, Ning , Wang, Gui-Qi, Fleischer, David, Dawsey, Sanford M.

Endoscopy | February 10, 2015 | Volume: 47 | Issue: 05 | Pages: 398-408

10.1055/s-0034-1391285 | PMID 25668428 Get It